LGX818 for Patients With BRAFV600 Mutated Tumors
Public ClinicalTrials.gov record NCT01981187. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 4 - LGX818 for Patients With BRAFV600 Mutated Tumors
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this signal seeking study is to determine whether treatment with LGX818 demonstrates sufficient efficacy in select pathway-activated solid tumors and/or hematologic malignancies to warrant further study
Study identification
- NCT ID
- NCT01981187
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 12 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 13, 2014
- Primary completion
- Aug 31, 2015
- Completion
- Oct 12, 2015
- Last update posted
- Mar 25, 2021
2014 – 2015
United States locations
- U.S. sites
- 13
- U.S. states
- 12
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Alabama Oncology St. Vincent's Birmingham | Birmingham | Alabama | 35211 | — |
| Highlands Oncology Group Highlands Oncology Group (22) | Fayetteville | Arkansas | 72703 | — |
| Yale University School of Medicine Smilow Cancer Hospital | New Haven | Connecticut | 06520 | — |
| Whittingham Cancer Center Norwalk Hospital | Norwalk | Connecticut | 06856 | — |
| Florida Cancer Specialists Florida Cancer Specialists (31 | Fort Myers | Florida | 33901 | — |
| Lurie Children's Hospital of Chicago Developmental Therapeutics | Chicago | Illinois | 60611 | — |
| Comprehensive Cancer Centers of Nevada CCC of Nevada (1) | Las Vegas | Nevada | 89109 | — |
| Genesis Cancer Services | Zanesville | Ohio | 43701 | — |
| University of Pennsylvania Presbyterian Medical Center University of Pennsylvania | Philadelphia | Pennsylvania | 19104 | — |
| Sanford Research Sanford Health | Sioux Falls | South Dakota | 57104 | — |
| Oncology Consultants Oncology Group | Houston | Texas | 77024 | — |
| Utah Cancer Specialists Utah Cancer Specialists (11) | Salt Lake City | Utah | 84106 | — |
| Shenandoah Oncology Shenadoah Oncology (2) | Winchester | Virginia | 22601 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01981187, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 25, 2021 · Synced Sep 3, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01981187 live on ClinicalTrials.gov.